[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,78,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644651","post-market-european--asian-registry-to-evaluate-the-minos-stent-graft-and-delivery-system-in-abdominal-aortic-aneurysm-treatment-100644651",false,"NCT07674173","Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment","A Prospective Multi-centre Observational Real-world Post-market European & Asian Registry With Low-profile Minos™ Abdominal Aortic Stent Graft","PEARL","Inclusion Criteria:\n\n* Diagnosis of infrarenal abdominal aortic aneurysm\n* Plan to treat with Minos Abdominal Aortic Stent-Graft and Delivery System\n* Voluntary participation and completion of Informed Consent Form, with willingness to participate in follow-up to 5 years post-procedure\n\nExclusion Criteria:\n\n* Subjects in whom use of the Minos™ Abdominal Aortic Stent-Graft and Delivery System is contraindicated, as follows:\n* Severe stenosis or calcification near the aneurysm, leading to difficulty in achieving apposition of vessel wall and stent graft.\n* Difficult access due to severe stenosis or tortuosity in the iliac artery or femoral artery.\n* Subjects with ruptured aneurysm or acute aneurysm.\n* Subjects with an infectious aneurysm.\n* Those who are allergic to contrast agents or unable to tolerate contrast agents due to renal insufficiency.\n* Patients with severe coagulation disorder and\u002For high risk of postoperative hemorrhage.\n* Aneurysmal neck angulation greater than 60°.\n* Patients with blood supply to vital organs originating from the aneurysmal sac.\n* Patients with other comorbidities and whose life expectancy does not exceed one year.\n* Subjects with connective tissue diseases, such as Marfan syndrome.\n* Minors and pregnant women.\n* Subjects who are allergic to nitinol.\n* Subjects who are considered not suitable for treatment with stent graft.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","5 Years","OBSERVATIONAL","The Minos™ Abdominal Aortic Stent-Graft and Delivery System is a medical device designed to treat abdominal aortic aneurysms using a minimally invasive procedure. The device is placed inside the aorta through blood vessels, usually accessed through small incisions in the groin. The goal of this observational study is to collect short-, medium- to long-term safety and performance data of the Minos™ stent-graft in everyday medical practice (real-world settings). The aim is to study about 200 patients worldwide and at least 30 patients in European hospitals.",[26],"Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft",[28,29,30],"Minos™ Abdominal Aortic Stent-Graft and Delivery System","EVAR","abdominal aortic aneurysm (AAA)","RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2023-03-05",{"date":39,"type":21},"2033-01-22",{"name":41,"class":42},"Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd","INDUSTRY",16,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":5},"100643960","european-multi-centre-post-market-registry-on-thoracic-endovascular-arch-repair-using-castor-and-cratos-100643960","NCT07668687","European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™","European Multi-Centre Castor™ and Cratos™ Branched Endovascular Arch Repair Registry","CEDAR","Inclusion Criteria:\n\n* Implantation of a Castor™ or Cratos™ single branch endoprothesis with incorporation of the left subclavian artery\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Patients allergic to the materials of the device;\n* Patients with severe or potentially systemic infections that increase the chance of graft infection;\n* Minors and pregnant women;\n* Branch for other supra-aortic vessels than the LSA\n* Rejection of participation.",{"count":53,"type":21},100,"The Castor™ and Cratos™ Branched Aortic Stent Graft Systems are medical devices designed for the minimally invasive endovascular treatment of thoracic aortic pathologies in the descending aorta. The goal of this multi-centre retrospective and prospective observational registry study is to capture the short-, medium- to long-term safety and performance data of how Castor™ and Cratos™ stent-grafts work in real-world settings (everyday medical practice). The aim is to study approximately 100 patients in European hospitals, with competitive enrollment.",[56,57,58,59,60,61],"Dissection of Thoracic Aorta","Dissection of Thoracic Descending Aorta","Aneurysm of Aorta, Thoracic","Penetrating Aortic Ulcers (PAUs)","Intramural Hematoma of the Thoracic Aorta","Ulcer-like Projection (ULP)",[63,64,65,66,67,68,69,70],"Castor™ Branched Aortic Stent Graft System","Cratos™ Branched Aortic Stent Graft System","TEVAR","thoracic aortic aneurysm (TAA)","Penetrating Aortic Ulcer (PAU)","Aortic Intramural Haematoma (IMH)","Ulcer-like projection (ULP)","thoracic aortic dissection",{"date":72,"type":35},"2026-06-25",{"date":74,"type":35},"2025-09-12",{"date":76,"type":21},"2033-12",{"name":41,"class":42},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100603699","prospective-multicenter-single-arm-study-of-aortic-arch-pathology-reconstruction-100603699","NCT07139912","Prospective, Multicenter, Single-Arm Study of Aortic Arch Pathology Reconstruction","Prospective, Multicenter, Single-Arm Trial Assessing Safety\u002FEffectiveness of Multi-Branch Thoracic Stent Grafts in Aortic Arch Disease","Inclusion Criteria:\n\n1. Aged 18 to 80 years\n2. Diagnosed with aortic arch pathology requiring intervention, including:\n\n   True aortic arch aneurysm\n\n   Pseudoaneurysm of the aortic arch\n\n   Penetrating aortic ulcer involving the arch\n3. Deemed suitable for endovascular repair by the investigating physician\n4. Capable of understanding study objectives, providing written informed consent, and complying with follow-up requirements\n5. Anatomic suitability confirmed by CTA:\n\n   Ascending aortic length ≥50 mm\n\n   Ascending aortic diameter ≥26 mm and ≤46 mm\n\n   Proximal landing zone length ≥20 mm\n\n   Brachiocephalic trunk diameter ≥9 mm and ≤19 mm with length ≥20 mm\n\n   Left common carotid artery (LCCA) and left subclavian artery (LSA) diameters ≥5 mm and ≤13 mm\n\n   LCCA length ≥20 mm\n\n   Distance from LSA ostium to left vertebral artery origin ≥20 mm\n6. High surgical risk per investigator assessment OR contraindicated for open surgery\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Connective tissue disorders affecting the aorta (e.g., Marfan syndrome, Ehlers-Danlos syndrome)\n3. Infected aortic pathologies or aortitis (e.g., mycotic aneurysm, Takayasu arteritis)\n4. Prior endovascular repair of ascending aorta\u002Faortic arch\n5. Documented allergy to nitinol, contrast media, or device materials\n6. Severe renal impairment:(Serum creatinine \\>2×ULN,Excluding dialysis-dependent patients)\n7. Hematologic abnormalities:(WBC \\\u003C3×10⁹\u002FL、Hb \\\u003C70 g\u002FL、PLT \\\u003C50×10⁹\u002FL)\n8. Heart transplant recipients\n9. Myocardial infarction or stroke within 3 months\n10. NYHA Class IV heart failure\n11. Active systemic infection (e.g., bacteremia, sepsis)\n12. Life expectancy \\\u003C12 months\n13. Mechanical aortic valve prosthesis impeding device delivery\n14. Current participation in other interventional trials with primary endpoint pending\n15. Anticipated poor compliance with follow-up\n16. Other contraindications for endovascular repair per investigator assessment:Severe vascular stenosis\u002Fcalcification\u002Ftortuosity\u002FThrombus at landing zones\u002FInability to cooperate with procedure","80 Years",{"count":87,"type":21},96,"INTERVENTIONAL",[90],"NA","A prospective ,multiple center Study about the Safety and Efficacy of the Thoracic Aortic Multi-Branch Stent Graft System, developed and manufactured by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., in patients with aortic arch pathologies.",[93],"Aortic Arch Disease","NOT_YET_RECRUITING","2025-08-18",{"date":97,"type":35},"2025-08-24",{"date":99,"type":21},"2025-09",{"date":101,"type":21},"2032-03",{"name":41,"class":42},1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":88,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":103},"100506424","cratos---evaluation-of-cratos-branch-stent-graft-system-in-treatment-of-descending-aorta-lesions-100506424","NCT05874206","CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions","Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions","Inclusion Criteria:\n\n1. Presence of thoracic aortic pathology (Dissection, including IMH and ULP; and PAU) deemed to warrant surgical repair which requires proximal graft placement in Zone 2\n2. Age ≥18 years at time of informed consent signature\n3. Informed Consent Form (ICF) is signed by Subject or legal representative\n4. Must have appropriate proximal aortic landing zone, defined as:\n\n   * Landing zone inner diameters between 23-41 mm\n   * The length of landing zone ≥15mm\n   * Landing without heavily calcified or heavily thrombosed\n   * Dissection Patients: Primary entry tear must be distal to LSA, and proximal extent of the proximal landing zone must not be dissected.\n   * For patients with prior replacement of the ascending aorta and\u002For aortic arch by a surgical graft, there must be at least 2 cm of landing zone proximal to the most distal anastomosis site.\n5. Must have appropriate LSA landing zone, defined as:\n\n   * Inner diameters of LSA 5-14 mm\n   * Minimum length of Left subclavian artery is 25 mm\n   * Target branch vessel landing zone must be in native aorta that cannot be severely tortuous , aneurysmal, dissected, heavily calcified, or heavily thrombosed.\n6. Must have appropriate distal aortic landing zone, defined as:\n\n   * Aortic inner diameters between 18-44 mm\n   * Landing zone cannot be heavily calcified, or heavily thrombosed.\n   * For isolated PAU, outer curvature length must be ≥ 2cm proximal to the celiac artery\n   * Landing zone in native aorta\n\nExclusion Criteria:\n\n1. Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta requiring repair\n2. Previous endovascular repair of the ascending aorta\n3. Infected aorta, active systemic infection\n4. Surgery within 30 days prior to enrolment with the exception of placement of vascular conduit for access .\n5. Life expectancy \\\u003C1 years\n6. Myocardial infarction within 6 weeks prior to treatment\n7. Stroke within 6 weeks prior to treatment.\n8. Pregnant or breastfeeding female\n9. Patient has an active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication) that may place the patient at increased risk of endovascular infection.\n10. Degenerative connective tissue disease, e.g., Marfan's or Ehlers-Danlos Syndrome\n11. Participation in another drug or medical device study within one year of study enrolment\n12. Known history of drug abuse within one year of treatment\n13. Tortuous or stenotic iliac and\u002For femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access\n14. Planned coverage of celiac artery\n15. Allergic to contrast agents, anaesthetics and delivery materials\n16. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin\n17. Patient with a history of a hypercoagulability disorder and\u002For is currently in a hypercoagulability state\n18. Persistent refractory shock (systolic blood pressure \\\u003C90 mm Hg)\n19. Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) \\\u003C30 (ml\u002Fmin\u002F1.73 m2) or currently requiring dialysis\n20. Contraindications to antiplatelet drugs and anticoagulants\n21. Investigator judged that not suitable for interventional treatment.",true,{"count":113,"type":21},130,[90],"The goal of this prospective, interventional, multicentre, single-arm performance objective study is to evaluate efficacy and safety of Cratos™ Branch Stent Graft System in treatment of lesions (dissection, IMH and PAU in descending aorta. The main question\\[s\\] it aims to answer are:\n\n* 30-day all-cause Mortality rate\n* Composite of the following events from the time of enrolment through 12-month:\n\n  * Device Technical Success\n  * Absence of: Aortic rupture, Lesion-related mortality, Disabling Stroke, Permanent paraplegia, Permanent paraparesis, New onset renal failure requiring permanent dialysis, Additional unanticipated post-procedural surgical or interventional procedure related to the device, procedure, or withdrawal of the device system\n\nParticipants will come for hospital office visits 1, 6, 12, 24-, 36-, 48- and 60-months post-procedure for the following, but not limited to assessments:\n\n* Physical examination\n* Modified Rankin scale\n* Tarlov scoring scale\n* CTA",[117,118,119],"Aortic Dissection Type B","Intramural Hematoma","Penetrating Aortic Ulcer","2025-02-24",{"date":122,"type":35},"2025-02-26",{"date":124,"type":35},"2024-03-08",{"date":126,"type":21},"2031-12",{"name":41,"class":42},""]